FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely anticancer therapy, and can be used for treating colon cancer. That is ensured by using the anticancer drug L-lysine-alpha-oxidase of Trichoderma cf. aureoviride Rifai BKMF-4268D, which is administered daily five times a day in equal portions in an integrated dose of 450-1000 Unit/kg, or administered five times every 48 hours in an integrated dose of 450 Unit/kg. A primary dose of the preparation makes 150 Unit/kg, while the rest of the preparation is administered in equal portions.
EFFECT: presented method of treating human colon cancer is more effective and less toxic.
3 ex, 3 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR TREATMENT OF SW620 HUMAN COLON CANCER IN EXPERIMENT | 2017 |
|
RU2665168C1 |
| METHOD OF LUNG CANCER TREATMENT | 2008 |
|
RU2365370C1 |
| LUNG CANCER THERAPY | 2008 |
|
RU2367436C1 |
| METHOD OF TREATING LUNG CANCER | 2009 |
|
RU2414894C1 |
| METHOD FOR PREPARING SUBSTANCE L-LYSINE-ALPHA-OXYDASE | 2011 |
|
RU2471866C1 |
| METHOD FOR OBTAINING AN ORTHOTOPIC PDX MODEL OF SQUAMOUS CELL CARCINOMA OF THE HUMAN ESOPHAGUS FOR THE STUDY OF RADIATION THERAPY IN AN EXPERIMENT | 2021 |
|
RU2760084C1 |
| METHOD OF SUPPRESSING GROWTH OF TUMOURS WITH GENETICALLY MODIFIED VERSION OF TRAIL CYTOKINE | 2019 |
|
RU2727059C1 |
| METHOD OF PRODUCTION OF SUBDERMAL XENOGRAFTS OF CELL LINE OF PEOPLE SKIN MELANOMA mel Cher WITH MUTATION V600E BRAF FOR PRECLINICAL STUDY OF ANTINEOPLASTIC TARGETED AGENTS | 2014 |
|
RU2572569C1 |
| SUBDERMAL XENOGRAFTS OF CELL LINE OF AMELANOTIC HUMAN SKIN MELANOMA MEL RAC WITH MUTATION NRAS FOR PRECLINICAL STUDY OF ANTINEOPLASTIC TARGETED AGENTS | 2016 |
|
RU2651939C2 |
| METHOD FOR OBTAINING AN ORTHOTOPIC PDX MODEL OF HUMAN BRAIN GLIOBLASTOMA ON IMMUNODEFICIENT MICE FOR PRECLINICAL STUDY OF ANTITUMOR EFFECTS OF CYTOSTATIC DRUGS | 2021 |
|
RU2761892C1 |
